ERNA earnings analysis
What we found in ERNA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ernexa Therapeutics reported a net loss of $5.5 million in Q1 2026, an improvement from a $8.2 million loss in Q1 2025, driven by an increase in operating expenses, including a significant goodwill impairment charge. Revenue remains absent as the company continues its pre-clinical development phase for its lead product candidate ERNA-101.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Reduction in Net Loss
- Net loss narrowed to $5.506 million in Q1 2026, compared to $8.202 million in Q1 2025, marking a $2.696 million improvement.
- Increased Operating Expenses
- Total operating expenses rose to $5.590 million in Q1 2026, up from $2.730 million in Q1 2025 due to heightened R&D costs and a goodwill impairment.
- Cash Position Improvement
- Cash increased by $7.293 million in Q1 2026, bolstered by $9.5 million from a public offering.
- No Revenue Reported
- The company reported no revenues for both Q1 2026 and Q1 2025, maintaining a zero revenue status.
- Goodwill Impairment
- Recognized a $2.0 million impairment of goodwill in Q1 2026 with no remaining goodwill balance as of March 31, 2026.
- Strong Cash Balance
- Cash on hand was approximately $9.2 million as of March 31, 2026, after accounting for cash used in operations.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Operating Losses
- Cumulatively, the company has an accumulated deficit of approximately $251.1 million as of March 31, 2026.
- Liquidity Risks
- Projected cash needs exceed current resources; as of April 30, 2026, cash was approximately $8.3 million, below operational requirements.
- Regulatory Approval Uncertainty
- The company remains in pre-clinical stages with no product sales or revenue, delaying potential future cash inflows.
What they said about what is next.
Company remains in pre-clinical stages and did not provide explicit forward guidance.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 13, 2026
- Ernexa is a preclinical synthetic allogeneic iMSC company focused on ERNA-101 (IL‑7/IL‑15) for platinum‑resistant ovarian cancer and ERNA‑201 (IL‑10) for autoimmune disease. The 2025 10‑K highlights regulatory progress…
- 10-Q · November 7, 2025
- Ernexa reported zero revenue for the three months ended September 30, 2025 and a net loss of $1,240 (loss per share $0.15). Cash rose to $3,047 (in thousands) following a $7.2 million equity raise in the nine months,…
- 10-Q · May 7, 2025
- Ernexa reported no revenue and a net loss of $(8,202) (three months ended March 31, 2025), or $(0.15) per share, driven by a $5,335 charge for a forward sales contract and lower operating expenses versus the prior year.…
- 10-K · March 12, 2025
- Eterna Therapeutics is a preclinical allogeneic iMSC cell therapy company that completed a material September/October 2024 recapitalization, in‑licensed a broad patent portfolio and entered an Exclusive License &…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ERNA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever